Novo Nordisk said the overhaul resulted in one-off costs of about DKK 9 billion in 2025, including DKK 5 billion in severance ...

Henrik Wulff, EVP of Manufacturing at Novo Nordisk, is stepping down after serving since 2015. The announcement came during the company's Q3 earnings report.

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

LONDON () -Wegovy maker Novo Nordisk said on Wednesday that its executive vice president in charge of manufacturing was ...

Dow Jones Top Company Headlines at 5 AM ET: Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster Drugs | XPeng ... Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster ...

Pfizer CEO Albert Bourla called Novo Nordisk's bid for obesity drug developer Metsera an "illegal...end-run around antitrust laws." ...

Pedersen and Maggie Fick COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts ...

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

(Reuters) -European shares hit a two-week low on Wednesday as elevated equity valuations continued to make investors nervous ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agree-on deal ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera.

COPENHAGEN () -Wegovy-maker Novo Nordisk lowered its full-year profit forecast on Wednesday in an early blow to the Danish ...